Skip to main content

Ketamine

EDM (Early Day Motion) 2943: tabled on 11 March 2026

Tabled in the 2024-26 session.

This motion has been signed by 13 Members. It has not yet had any amendments submitted.

Motion text

That this House notes with concern the increased problematic use of ketamine, particularly among young people; further notes that its severe impacts can include cognitive impairment, psychological difficulties and physical damage to the bladder, kidneys and urinary tract, leading to dependency and contributing to deaths; recognises that those affected may require incontinence pads or surgery; pays tribute to those providing peer-support in friendly, safe groups free from stigma; supports the recommendations of the Advisory Council on the Misuse of Drugs (ACMD) advising against the reclassification of the drug from a Class B to a Class A controlled substance; recognises that previous punitive policies have proven to be ineffective and often counter-productive; advocates a public health-centred harm reduction approach, providing access to evidence-based education and effective treatment; and urges the Government to adopt the recommendations of the ACMD, raise awareness of ketamine-related harms and promote the expansion of education, treatment and support services.